Last updated on: 07/02/2014
Name of organisation
1) Department/Research group
2) Organisation/affiliationOptum
Short Name in the inventoryOptum
Administrative Contact
Title Ms
Last name Spannheimer
First name Andrea
Address line 1Boehmerwaldstr. 2
Address line 2
Address line 3
CityGrasbrunn
Postcode85630
CountryGermany
Phone number (incl. country code)004989666105104
Alternative phone number00491726658398
Fax number (incl. country code)
Scientific Contact
Title Ms
Last name Spannheimer
First name Andrea
Address line 1Boehmerwaldstr. 2
Address line 2
Address line 3
CityGrasbrunn
Postcode85630
CountryGermany
Phone number (incl. country code)004989666105104
Alternative phone number00491726658398
Fax number (incl. country code)
Alternative Scientific Contact
Title Ms
Last name Tanja
First name Hultsch
Address line 1Wappenhalle
Address line 2Konrad-Zuse-Platz 8
Address line 3
CityMunich
Postcode81829
CountryGermany
Phone number (incl. country code)4989666105103
Alternative phone number
Fax number (incl. country code)
2. Description
Optum is a member of the UnitedHealth Group family of companies. Optum is specialized in the conduct of late phase research, PASS, health economics & outcomes research, patient reported outcomes research & market access & reimbursement. Optum was orginally named Ingenix & was formed in 1999 to create the industry's leading health data & information firms combined into one organization. Optum is among the largest health information & data company in the world. Optum provides knowledge & information services to physicians & health care professionals, health insurers, employers & health care buyers, pharmaceutical & biotechnology companies, medical device manufacturers, & government entities. Optum offers a wide range of services to the pharmaceutical industry, including clinical trial, safety, epidemiology & pharmacoeconomic studies using administrative claims data. Optum offers a variety of data products to provide market-based answers to specific questions.
3. Category
For profit organisation
4. Available resources
In houseVia Contacts/Network
Project Management and Monitoring
Yes
No
Data Management, Medical Writing
Yes
No
Health Economics, PROs, Modelling and MAR
Yes
No
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Cardiovascular diseases
Congenital Malformations
Devices
Disorders of the central nervous system
Ear, nose and oropharynx disorders
Endocrine disorders
Eye disorders
Gastrointestinal tract
Geriatrics
Gynaecology
Immunological products and vaccines
Immunosuppression
Infectious diseases
Liver disease
Malignant disease
Musculoskeletal and joint diseases
Neonates
Nutrition and blood
Osteoporosis
Paediatrics
Pregnancy
Psychiatry
Renal impairment
Respiratory diseases
Skin disorders
Epidemiologic Studies/Methods
Neurology
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Case Control Study
Drug Utilisation
Interventional Clinical Trial
Meta-Analysis
Patient Registries
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Greater than 5
Number of patients/respondents involved in the study(ies)
Less than 150
Between 150 and 1499
Between 1500 and 14999
Greater than 15000
8. Access to data collection resources
Capacity to conduct face-to-face interviews
Yes
In a clinic
Yes
In the community
Yes
Electronic data capture systems
Yes
System used:
Smart Measurement (proprietary system)
Interactive voice response systems
Yes
Call centre
Yes
9. Experience in secondary research and meta-analysis
Yes
10. Work with existing data resources in the past 3 years
Name of data resourceNo. of studies
Commercial health insurance claims data (Inc Ingenix normative health info. database, Healthcore Integrated Research database, PharMetrics database)30
Abstract medical records30
Electronic medical records (Inc GPRD & THIN)2
Registries (Inc National Cancer, fracture incidence, NPR Scandinavia, Prescriptive pharma. Scandinavia, Insurance board Scandinavia, Swedish dementia)56
EMR data linkage in primary care5
11. Registries established by centre
None
12. Experience in collaboration in a study team
Collaborating Investigator
13. Current involvement in research networks
None
14. Interest in research opportunities which are funded
By pharmaceutical companies
By charities
By government
By research councils
By EU funding schemes
15. Interest in contract research only if free to publish results
No
16. Selected publications of the last 5 calendar years
ReferenceLink to web-publication
PT J AU Wimo, A Winblad, B Jonsson, L AF Wimo, Anders Winblad, Bengt Jonsson, Linus
TI An estimate of the total worldwide societal costs of dementia in 2005
SO ALZHEIMERS & DEMENTIA
AB Background: The aim of this report was to estimate the worldwide cost of dementia in 2005 from a societal viewpoint.
Methods: Costs were estimated by combining prevalence estimates, country and region specific data on Gross Domestic Product per person, and average wage with results from previously published cost-of-illness studies in different countries. Direct medical and nonmedical costs as well as costs for informal care were included.
Results: The total worldwide societal cost of dementia, on the basis of a dementia population of 29.3 million persons, was estimated to be US$315.4 billion in 2005, including US$105 billion for informal care (33%). Seventy-seven percent of the total costs occurred in the more developed regions, with 46% of the prevalence.
Conclusions: Worldwide costs for dementia are enormous, and informal care constitutes a major cost component, in particular in less developed regions. The health economics of dementia is a highly relevant area for further research. (c) 2007 The Alzheimer's Association. All rights reserved.
SN 1552-5260, PD APR, PY 2007, VL 3, IS 2, BP 81, EP 91, DI 10.1016/j.jalz.2007.02.001, UT ISI:000249579900003, ER
PT, J, AU Kobelt, G, Berg, J, Lindgren, P, Fredrikson, S, Jonsson, B, AF
Kobelt, G., Berg, J., Lindgren, P., Fredrikson, S., Jonsson, B.
TI
Costs and quality of life of patients with multiple sclerosis in Europe
SO
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
AB
Objective: To assess overall resource consumption, work capacity and quality of life of patients with multiple sclerosis in nine European countries.
Methods: Information on resource consumption related to multiple sclerosis, informal care by relatives, productivity losses and overall quality of life (utility) was collected with a standardised pre-tested questionnaire from 13186 patients enrolled in national multiple sclerosis societies or followed up in neurology clinics. Information on disease included disease duration, self-assessed disease severity and relapses. Mean annual costs per patient (Euro, 2005) were estimated from the societal perspective.
Results: The mean age ranged from 45.1 to 53.4 years, and all levels of disease severity were represented. Between 16% and 29% of patients reported experiencing a relapse in the 3 months preceding data collection. The proportion of patients in early retirement because of multiple sclerosis ranged from 33% to 45%. The use of direct medical resources (eg, hospitalisation, consultations and drugs) varied considerably across countries, whereas the use of non-medical resources (eg, walking sticks, wheel chairs, modifications to house and car) and services (eg, home care and transportation) was comparable. Informal care use was highly correlated with disease severity, but was further influenced by healthcare systems and family structure. All types of costs increased with worsening disease. The total mean annual costs per patient (adjusted for gross domestic product purchasing power) were estimated at Euro 18000 for mild disease (Expanded Disability Status Scale (EDSS) < 4.0), Euro 36500 for moderate disease (EDSS 4.0-6.5) and Euro 62000 for severe disease (EDSS > 7.0). Utility was similar across countries at around 0.70 for a patient with an EDSS of 2.0 and around 0.45 for a patient with an EDSS of 6.5. Intangible costs were estimated at around Euro 13000 per patient.
SN 0022-3050, PD AUG, PY 2006, VL 77, IS 8, BP 918, EP 926, DI 10.1136/jnnp.2006.090365, UT ISI:000239037600007, ER
Enger C, Gately R, Ming EE, Niemcryk SJ, Williams L, McAfee AT. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am J Cardiol. 106:1594-1601, 2010.
Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. New England Journal of Medicine 2008;358:771-83.
Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007;110(3): 587-593.
